Symptoms of prostate cancer may include needing to urinate more frequently; having to rush to the toilet; straining to ...

Prostate cancer is the most common form of cancer in men in 112 countries, with cases expected to double by 2040. The post ...

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

Men who consistently avoid prostate cancer screening appointments face a much higher risk of dying from the disease, ...

Prostate cancer affects one in eight men during their lifetime, making it the second most common cancer among American males.

"But if you're 50 and have 25 to 30 years in which prostate cancer can become a bigger issue, even with the downsides, most ...

Telix Pharmaceuticals' said its new drug application in the U.S. for an imaging agent received regulatory approval. The Melbrourne, Australia-based biopharmaceutical company said Friday that the Food ...

The company stated that although it has dropped vobra duo, it remains optimistic about its other candidate MGC026.

First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone and with other drug combinations.

A 68-year-old man with prostate cancer develops penile metastases, a rare but serious complication, reinforcing the need for ...

Men who consistently avoid prostate cancer screening appointments face a disproportionately higher risk of dying from the disease, finds research identifying a new high-risk group.

Lu rhPSMA-10.1 showed high tumor radiation with low healthy tissue exposure in a phase 1/2 trial for metastatic ...